TNFAIP3 Antibody

中文名稱：

TNFAIP3兔多克隆抗體
貨號：

CSB-PA023958LA01HU
規格：

￥440
圖片：
Western Blot
Positive WB detected in: RAW264.7 whole cell lysate, Hela whole cell lysate, A549 whole cell lysate
All lanes: TNFAIP3 antibody at 2.7µg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 90 kDa
Observed band size: 90 kDa

Immunofluorescent analysis of Hela cells using CSB-PA023958LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) TNFAIP3 Polyclonal antibody
Uniprot No.：

P21580
基因名：

TNFAIP3
別名：

A20 antibody; AISBL antibody; MGC104522 antibody; MGC138687 antibody; MGC138688 antibody; OTU domain containing protein 7C antibody; OTU domain-containing protein 7C antibody; OTUD7C antibody; Putative DNA binding protein A20 antibody; Putative DNA-binding protein A20 antibody; TNAP3_HUMAN antibody; TNF alpha-induced protein 3 antibody; TNFA1P2 antibody; TNFAIP 3 antibody; TNFAIP3 (A20) antibody; TNFAIP3 antibody; Tumor necrosis factor alpha induced protein 3 antibody; Tumor necrosis factor alpha-induced protein 3 antibody; Tumor necrosis factor induced protein 3 antibody; Tumor necrosis factor inducible protein A20 antibody; tumor necrosis factor, alpha-induced protein 3 antibody; Zinc finger protein A20 antibody
宿主：

Rabbit
反應種屬：

Human, Mouse
免疫原：

Recombinant Human Tumor necrosis factor alpha-induced protein 3 protein (97-183AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，TNFAIP3 Antibody (CSB-PA023958LA01HU)，的標記方式是Non-conjugated。對于TNFAIP3 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA023958LB01HU	TNFAIP3 Antibody, HRP conjugated	ELISA
FITC	CSB-PA023958LC01HU	TNFAIP3 Antibody, FITC conjugated
Biotin	CSB-PA023958LD01HU	TNFAIP3 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:2000-1:10000
IF	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages.
基因功能參考文獻：
1. Analysis of postmortem brain tissue and CSF of multiple sclerosis (MS) patients revealed that expression of A20/TNFAIP3, as well as the expression levels of IL-1beta and NLRP3 were significantly increased in MS plaques. PMID: 29789522
2. LIFR-AS1 serves as a competitive endogenous RNA for miR-29a to inhibit its expression and up-regulate downstream target TNFAIP3 expression, finally modulating the resistance of colorectal cancer to pohotodynamic therapy. PMID: 29807108
3. Study demonstrates evidence of the constitutive expression of A20 in macrophages, its role in supporting the differentiation program, and the functional consequences of the zinc finger domains thereof. PMID: 28771803
4. A20 dimers bind linear ubiquitin to stabilize the Ripoptosome and potentiate its apoptosis-inducing activity. PMID: 30209212
5. At least in the subcutaneous fat of humans and mice, the levels of PGC-1a decrease during obesity, while its physical association with A20 increases. PMID: 29678181
6. Results suggest a clinicopathologic implication of A20 in progression of NKTL. PMID: 29380463
7. Studied effect of temperature on gene expression regulation by NF-kappabeta on TNF alpha induced protein 3 (A20) transcription. PMID: 29760065
8. TNFAIP3 abnormality was less prevalent among intestinal diffuse large B-cell lymphomas with some discordancy between gene deletion and protein expression. PMID: 29463935
9. antidepressant treatment exerts anti-inflammatory effects, at least in part through increased expression of the TNFAIP3 gene PMID: 27640899
10. A20 regulates canonical wnt-signaling through an interaction with RIPK4 PMID: 29718933
11. these results suggested that in human colorectal cancer cells, A20 may function to inhibit cancer progression via down-regulation of TNFalpha-induced chemokine production by suppression of ERK signaling PMID: 29175508
12. Low A20 expression is associated with HIV disease. PMID: 29505600
13. A20 overexpression in vivo significantly reduced renal injury as demonstrated by the improved levels of Scr and BUN and the reduction in histological damage. PMID: 29067462
14. the risk allele for the TNFAIP3 rs2230926 polymorphism was associated with systemic lupus erythematosus susceptibility. PMID: 29783072
15. It was concluded that the A20 protein in macrophages modulates lung injury induced by LPS. The overexpression of A20 in macrophages may be involved in modulating macrophage polarization. PMID: 28791391
16. TNF phase III signalling displays ongoing TNFR1/NF-kappa B activation in monocytic cells. High- and low-sensitive genes are induced including differentially regulated A20. A20 strictly controls this signalling in an IKK- and partially RIP-dependent manner. The A20-mediated control mechanisms are supported by ABIN1 and CYLD. PMID: 28629782
17. A20 is a negative regulator of inflammation in human myometrium and foetal membranes. PMID: 28911210
18. The tandem polymorphisms (rs148314165, rs200820567), deletion T followed by a T to A transversion and collectively referred to as TT > A variant of TNFAIP3 may be associated with the susceptibility of chronic hepatitis B virus infection but not the clinical disease. PMID: 28784141
19. elevated A20 expression is involved in the severity of chronic hepatitis B PMID: 28473659
20. The results of this study confirmed that the A20 expression is reduced in whole blood of Multiple Sclerosis patients as compared to healthy control. PMID: 28337659
21. C/EBP beta LAP isoform expression was increased and LIP/TNFAIP3/TNIP1 expression was decreased in systemic lupus erythematosus (SLE) patients. LAP expression was positively correlated with SLE disease activity; TNFAIP3 and TNIP1 expression was negatively correlated with SLE disease activity. PMID: 27659348
22. A20 may have a role in the progression of chronic HBV infection PMID: 27634895
23. A20 overexpression inhibits hepatic stellate cell activation, which could be the mechanism for high A20 expression protected livers from fibrosis. PMID: 28251449
24. The data demonstrate that miR-125b regulates nasopharyngeal carcinoma cell proliferation and apoptosis by targeting A20/NF-kappaB signaling pathway, and miR-125b acts as oncogene, whereas A20 functions as tumor suppressor. PMID: 28569771
25. we demonstrate that a pathological reduction in TNFAIP3 levels induced NF-kappaB/SMAD7 pathway activation, causing a deficiency in MSCs in ITP patients. The ability of ITP-MSCs to support megakaryocytic differentiation and thrombopoiesis of CD34(+) cells was impaired. PMID: 29327472
26. miR-125b regulates differentiation and reprogramming of T cell glucose metabolism via targeting A20 in T cell acute lymphoblastic leukemia. PMID: 27637078
27. Review/Meta-analysis: TNFAIP3 gene rs10499194, rs13207033 polymorphisms decrease the risk of rheumatoid arthritis, especially among Caucasian populations. PMID: 27779104
28. In vitro deletion of A20 in B cells compromised the expression of IL10. PMID: 27825134
29. Low A20 expression is associated with hepatocellular carcinoma. PMID: 26909601
30. The results suggest that TNFAIP3 polymorphisms (rs2230926, rs5029937, rs5029939, and rs3757173) are associated with susceptibility to systemic lupus erythematosus. (Meta-analysis) PMID: 27726311
31. Hepatitis C virus core protein ligates gC1qR to induce A20 expression in macrophages via P38, JNK and NF-kappaB signaling pathways, which leads to a low-grade chronic inflammation during HCV infection. PMID: 27183919
32. Results show that TNFAIP3 expression is regulated by miR-19b through targeting its 3'-UTR which contributes to the radioresistance of nasopharyngeal carcinoma and consequently activating the NF-kappaB pathway. PMID: 27919278
33. demonstrates that TNFAIP3 gene polymorphisms (rs2230926 and rs5029937) are associated with the increased risk of rheumatoid arthritis. [META-ANALYSIS] PMID: 28888761
34. CHN1 and TNFAIP3 are candidate biomarkers for esophageal squamous cell carcinomas PMID: 27072986
35. These results identify the ubiquitin-editing enzyme A20 as a novel endogenous mechanism for negative regulation of fibrotic response intensity PMID: 27716397
36. Our data propose an additional novel mechanism to explain the known NF-kappaB inhibitory effects of A20: by affecting p105 ubiquitination and subsequently its degradation and limited processing. PMID: 28923245
37. A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1. PMID: 28892081
38. Low TNFAIP3 expression is associated with colitis-associated colorectal cancer. PMID: 27991929
39. The miR-17-92 is a critical contributor to CML leukemogenesis via targeting A20 and activation of NF-kappaB signaling. PMID: 28461114
40. IM could upregulate A20 protein to inhibit the activation of NF-kappaB pathway in Jurkat T cells, which was independent of the ABIN1 protein. PMID: 28502291
41. this meta-analysis confirms that TNFAIP3 gene polymorphisms may play important roles in the pathogenesis of Rheumatoid arthritis PMID: 28199970
42. Report a significant association between the biased usage of IGHV4-34 (binds to the carbohydrate I/i antigens) and inactivating mutation of TNFAIP3 [encoding a global negative regulator of the canonical nuclear factor-kappaB (NF-kappaB) pathway] in ocular adnexal MALT lymphomas. PMID: 28682481
43. reduced expression confers susceptibility to psoriasis PMID: 28658319
44. Haploinsufficiency of TNFAIP3 (A20) by a germline heterozygous mutation leads to the autoimmune lymphoproliferative syndrome (ALPS) phenotype. PMID: 27845235
45. These results suggested that A20 is involved in regulating intracerebral hemorrhage-induced inflammatory injury in both the central and peripheral system PMID: 27986908
46. In targeted sequencing, a disruptive mutation of TNFAIP3 was the most common alteration (54%), followed by mutations of TBL1XR1 (18%) and cAMP response element binding proteins (CREBBP) (17%). PMID: 28152507
47. the DNA fragment containing the associated SNPs interacts through chromatin looping not only with TNFAIP3, but also with IL20RA, located 680 kb upstream. PMID: 27799070
48. The findings suggest that TNFAIP3 protein may be an independent prognostic marker for poor survival, and a promising target for esophageal squamous cell carcinoma therapy. PMID: 28197630
49. Study demonstrates that the rs7749323 in the TNFAIP3 gene is strongly associated with the late onset myasthenia gravis(with positive AChR Ab but without thymoma). PMID: 28514294
50. Influenza a virus NS1 has a role in inducing A20 contributes to viral replication by suppressing interferon-induced antiviral response PMID: 27914808
顯示更多

收起更多
相關疾?。?/div>
Autoinflammatory syndrome, familial, Behcet-like (AISBL)
亞細胞定位：

Cytoplasm. Nucleus. Lysosome.; [A20p50]: Cytoplasm.
蛋白家族：

Peptidase C64 family
數據庫鏈接：

HGNC: 11896

OMIM: 191163

KEGG: hsa:7128

STRING: 9606.ENSP00000237289

UniGene: Hs.211600

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human